A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
收藏DataCite Commons2025-11-14 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006545/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus
tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive
(HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
提供机构：
Vivli
创建时间：
2021-01-13
